High-Dose IL-2 and SAbR for Metastatic Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
Clin. Cancer Res 2021 Sep 22;[EPub Ahead of Print], R Hannan, O Mohamad, A Diaz de Leon, S Manna, LM Pop, Z Zhang, S Mannala, A Christie, S Christley, N Monson, D Ishihara, EJ Hsu, C Ahn, P Kapur, M Chen, Y Arriaga, K Courtney, B Cantarel, EK Wakeland, YX Fu, I Pedrosa, L Cowell, T Wang, V Margulis, H Choy, RD Timmerman, J BrugarolasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.